The application of population pharmacokinetic modeling to individualized antibiotic therapy

International Journal of Antimicrobial Agents

Volumn 19, Issue 4, 2002, Pages 313-322

  Vinks, Alexander A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Bayesian forecasting; Pharmacokinetic pharmacodynamic modeling; Population pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; LEVOFLOXACIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BAYES THEOREM; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG HALF LIFE; HUMAN; MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION DYNAMICS; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG MONITORING; DRUG THERAPY; HUMANS; MALE; MATHEMATICAL COMPUTING; METHODS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0036223185     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00023-7     Document Type: Conference Paper

References (36)

1. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. The 'wooden shoe' paradigm
2. Population pharmacokinetics
3. Model-based, goal-oriented, individualised drug therapy. Linkage of population modeling, new 'multiple model' dosage design, bayesian feedback and individualised target goals
4. The geometry of mixture likelihoods: a general theory
5. A maximum likelihood estimation method for random coefficient regression models
6. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model
7. Forecasting individual pharmacokinetics
8. Software for population pharmacokinetics and pharmacodynamics
9. Nonparametric EM algorithms for estimating prior distributions
10. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control
11. Tobramycin population pharmacokinetics in neonates
12. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes
13. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis
14. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations
15. Dosage adjustment for ceftazidime in patients with impaired renal function
16. Population modeling in drug development
17. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside
18. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents
19. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
20. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation
21. Is continuous infusion of β-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations
22. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
23. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions
24. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion
25. Dosage regimens od antibacterials. Implications of a pharmacokinetic/pharmacodynamic model
26. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions
27. Development of gentamicin population models for ICU and non-ICU patients using a nonparametric algorithm (NPEM)
28. Pharmacokinetic modeling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm
29. Pharmacokinetics and dose requirements of vancomycin in neonates
30. Population pharmacokinetic study of teicoplanin in severely neutropenic patients
31. Pharmacokinetics and tissue concentrations of cefuroxime
32. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency
33. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy
34. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin
35. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection